Olanzapine Aurobindo

Olanzapine, the active ingredient in Olanzapine Aurobindo, is a atypical antipsychotic presented as a tablet for oral use. It is primarily prescribed for the management of schizophrenia and bipolar I disorder in adults. GNH USA supplies Olanzapine Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olanzapine Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine Aurobindo is an atypical antipsychotic used in the treatment of several psychiatric conditions.

- Schizophrenia: reduces psychotic symptoms such as delusions, hallucinations and thought disorder. - Bipolar I disorder (manic episodes): helps control mood swings and prevents escalation of manic symptoms. - Schizoaffective disorder: alleviates both psychotic and mood components of the illness. - Psychotic depression: augments antidepressant therapy by addressing residual psychotic features. - Maintenance therapy: supports long‑term stability and reduces risk of relapse in chronic psychotic disorders.

Olanzapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Weight gain: increased appetite leading to gradual weight increase. - Sedation: drowsiness or feeling of being unusually tired. - Dry mouth: reduced salivation causing oral dryness. - Constipation: slowed gastrointestinal motility. - Elevated triglycerides: rise in blood lipid levels. - Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare, life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements, often of the face. - Hyperglycaemia: significant rise in blood glucose, potentially precipitating diabetes. - Seizures: increased risk of convulsive episodes. - Agranulocytosis: severe reduction in white blood cells. - Hepatotoxicity: liver enzyme elevations indicating possible liver injury.

When prescribing Olanzapine Aurobindo, clinicians should consider several safety aspects.

- Monitor metabolic parameters: regularly check weight, fasting glucose and lipid profile. - Assess for cardiovascular risk: evaluate blood pressure and heart rate, especially in patients with pre‑existing hypertension. - Screen for movement disorders: watch for early signs of tardive dyskinesia or extrapyramidal symptoms. - Evaluate hepatic function: perform baseline liver function tests and repeat as needed. - Use caution in the elderly: increased sensitivity to sedation and orthostatic hypotension. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture and direct sunlight.

Olanzapine Aurobindo can interact with several other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may raise olanzapine plasma levels, increasing toxicity risk. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression. - Anticholinergic agents: may exacerbate dry mouth and constipation.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, rifampicin): may lower olanzapine concentrations, reducing therapeutic effect. - Smoking: induces CYP1A2 and can decrease drug exposure. - Lithium: combined use may increase the risk of neurotoxic effects.